Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) saw some unusual options trading activity on Wednesday. Investors purchased 1,796 call options on the stock. This represents an increase of approximately 15% compared to the typical daily volume of 1,556 call options.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Manchester Capital Management LLC raised its stake in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares during the last quarter. Sunbelt Securities Inc. lifted its holdings in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares during the period. Huntington National Bank lifted its holdings in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. purchased a new position in Sarepta Therapeutics in the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Royal Bank of Canada reduced their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. HC Wainwright restated a "sell" rating and set a $75.00 target price on shares of Sarepta Therapeutics in a report on Wednesday. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday. Needham & Company LLC reissued a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Finally, Scotiabank cut their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a report on Thursday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $167.41.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT traded up $0.65 during trading on Friday, reaching $74.10. 2,591,321 shares of the company traded hands, compared to its average volume of 1,218,291. The firm has a 50 day simple moving average of $107.19 and a 200-day simple moving average of $117.88. Sarepta Therapeutics has a 52-week low of $73.05 and a 52-week high of $173.25. The stock has a market capitalization of $7.19 billion, a PE ratio of 59.28 and a beta of 0.79. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.